Rapport Therapeutics (RAPP) Treasury Shares (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Treasury Shares of $295413.0 for Q1 2026, up 2012.05% year-over-year from $13987.0 in Q1 2025, and down 28.27% quarter-over-quarter from $411833.0 in Q4 2025.
Rapport Therapeutics (RAPP) Treasury Shares (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Treasury Shares for 4 consecutive years, with $295413.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares rose 2012.05% year-over-year to $295413.0; the TTM figure through Mar 2026 stood at $295413.0 (up 2012.05% YoY), while the FY2025 annual figure was $411833.0, down 57.83% from the prior year.
- Treasury Shares slipped to $295413.0 in Q1 2026 per RAPP's latest filing, from $411833.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $100.2 million in Q2 2023 and bottomed at $13987.0 in Q1 2025.
- Historically, Treasury Shares has averaged $33.8 million across 4 years, with a median of $1.0 million in 2024.
- Annual changes were most pronounced in 2025 — Treasury Shares plunged 99.99% — and 2026, when it soared 2012.05%.
- Rapport Therapeutics' Treasury Shares stood at $100.2 million in 2023, then plunged by 99.03% to $976596.0 in 2024, then plunged by 57.83% to $411833.0 in 2025, then declined by 28.27% to $295413.0 in 2026.
- Business Quant data shows RAPP's Treasury Shares at $295413.0 in Q1 2026, $411833.0 in Q4 2025, and $544235.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 212,856.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 212,856.00 |
| Jun 30, 2026 | 212,856.00 |
| Mar 31, 2026 | 295,413.00 |
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 295,413.00 |
| Dec 31, 2025 | 411,833.00 |
| Dec 31, 2025 | 411,833.00 |
| Sep 30, 2025 | 544,235.00 |
| Sep 30, 2025 | 544,235.00 |
| Jun 30, 2025 | 304,253.00 |
| Jun 30, 2025 | 304,253.00 |
| Mar 31, 2025 | 13,987.00 |
| Mar 31, 2025 | 13,987.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 976,596.00 |
| Dec 31, 2024 | 976,596.00 |
| Sep 30, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.12 Mn |